MX2014005635A - Derivados de 2 - (1,2,3 -triazol - 2 - il) benzamida y 3 - (1,2,3 - triazol - 2 - il) picolinamida. - Google Patents

Derivados de 2 - (1,2,3 -triazol - 2 - il) benzamida y 3 - (1,2,3 - triazol - 2 - il) picolinamida.

Info

Publication number
MX2014005635A
MX2014005635A MX2014005635A MX2014005635A MX2014005635A MX 2014005635 A MX2014005635 A MX 2014005635A MX 2014005635 A MX2014005635 A MX 2014005635A MX 2014005635 A MX2014005635 A MX 2014005635A MX 2014005635 A MX2014005635 A MX 2014005635A
Authority
MX
Mexico
Prior art keywords
triazol
benzamide
receptor antagonists
orexin receptor
amide derivatives
Prior art date
Application number
MX2014005635A
Other languages
English (en)
Other versions
MX343837B (es
Inventor
Christoph Boss
Martin Bolli
Christine Brotschi
Bibia Heidmann
Thierry Sifferlen
Jodi T Williams
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of MX2014005635A publication Critical patent/MX2014005635A/es
Publication of MX343837B publication Critical patent/MX343837B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Addiction (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

La presente invención se refiere a derivados de 2-(1,2,3-triazol-2-il)benzamida y 3-(1,2,3-triazol-2-iI)picolinami da de la fórmula (I): (ver Fórmula) en donde Ar1, Q y R1 a R5 se definen según lo referido en la descripción; a su preparación; a sus sales farmacéuticamente aceptables; y a su uso como productos farmacéuticos; a composiciones farmacéuticas que contienen uno o más compuestos de la fórmula (I); y en especial, a su uso como antagonistas del receptor de orexina.
MX2014005635A 2011-11-08 2012-11-07 Derivados de 2 - (1,2,3 -triazol - 2 - il) benzamida y 3 - (1,2,3 - triazol - 2 - il) picolinamida. MX343837B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IB2011054976 2011-11-08
PCT/IB2012/056218 WO2013068935A1 (en) 2011-11-08 2012-11-07 2-(1,2,3-triazol-2-yl)benzamide and 3-(1,2,3-triazol-2-yl)picolinamide derivatives as orexin receptor antagonists

Publications (2)

Publication Number Publication Date
MX2014005635A true MX2014005635A (es) 2014-06-23
MX343837B MX343837B (es) 2016-11-24

Family

ID=47258050

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014005635A MX343837B (es) 2011-11-08 2012-11-07 Derivados de 2 - (1,2,3 -triazol - 2 - il) benzamida y 3 - (1,2,3 - triazol - 2 - il) picolinamida.

Country Status (28)

Country Link
US (1) US9150566B2 (es)
EP (1) EP2776430B1 (es)
JP (1) JP5718535B2 (es)
KR (1) KR101676930B1 (es)
CN (1) CN103917538B (es)
AR (1) AR088692A1 (es)
AU (1) AU2012335194B2 (es)
BR (1) BR112014010617B1 (es)
CA (1) CA2846568C (es)
CL (1) CL2014000659A1 (es)
CY (1) CY1117638T1 (es)
DK (1) DK2776430T3 (es)
EA (1) EA024106B1 (es)
ES (1) ES2572703T3 (es)
HK (1) HK1199022A1 (es)
HR (1) HRP20160678T1 (es)
HU (1) HUE029239T2 (es)
IL (1) IL232462A (es)
IN (1) IN2014CN04127A (es)
MX (1) MX343837B (es)
MY (1) MY167791A (es)
PL (1) PL2776430T3 (es)
SG (1) SG11201401665WA (es)
SI (1) SI2776430T1 (es)
TW (2) TWI555747B (es)
UA (1) UA112317C2 (es)
WO (1) WO2013068935A1 (es)
ZA (1) ZA201404189B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9440982B2 (en) 2012-02-07 2016-09-13 Eolas Therapeutics, Inc. Substituted prolines/piperidines as orexin receptor antagonists
JP6346862B2 (ja) 2012-02-07 2018-06-20 エオラス セラピューティクス， インコーポレイテッド オレキシンレセプターアンタゴニストとしての置換プロリン／ピペリジン
US9732075B2 (en) 2012-06-04 2017-08-15 Idorsia Pharmaceuticals Ltd Benzimidazole-proline derivatives
WO2014141065A1 (en) 2013-03-12 2014-09-18 Actelion Pharmaceuticals Ltd Azetidine amide derivatives as orexin receptor antagonists
SI3077389T1 (en) 2013-12-03 2018-01-31 Idorsia Pharmaceuticals Ltd (S) - (2- (6-CHLORO-7-METHYL-1 H-BENZO (D) IMIDAZOL-2-YL) -2-METHYLPYROLIDIN-1-YL (5-METHOXY-2- (2H- , 2,3-TRIAZOL-2-IL) PHENYL) METHANONE AND ITS USE AS ANTAGONISTS OF OREXIN RECEPTOR
UA119151C2 (uk) 2013-12-03 2019-05-10 Ідорсія Фармасьютікалз Лтд КРИСТАЛІЧНА СОЛЬОВА ФОРМА (S)-(2-(6-ХЛОР-7-МЕТИЛ-1H-БЕНЗО[d]ІМІДАЗОЛ-2-ІЛ)-2-МЕТИЛПІРОЛІДИН-1-ІЛ)(5-МЕТОКСИ-2-(2H-1,2,3-ТРИАЗОЛ-2-ІЛ)ФЕНІЛ)МЕТАНОНУ ЯК АНТАГОНІСТ ОРЕКСИНОВОГО РЕЦЕПТОРА
WO2015083094A1 (en) 2013-12-04 2015-06-11 Actelion Pharmaceuticals Ltd Use of benzimidazole-proline derivatives
JP2017024990A (ja) * 2013-12-13 2017-02-02 大正製薬株式会社 オキサゾリジン及びオキサジナン誘導体
CN105814042B (zh) * 2013-12-13 2018-09-28 大正制药株式会社 噁嗪烷化合物的晶形及其制造方法
US9968624B2 (en) 2014-05-16 2018-05-15 The University Of Tokyo Depression treatment agent
EP3180332B1 (en) 2014-08-13 2021-10-27 Eolas Therapeutics Inc. Difluoropyrrolidines as orexin receptor modulators
WO2016095205A1 (en) 2014-12-19 2016-06-23 Merck Sharp & Dohme Corp. Heteroaryl orexin receptor antagonists
CN104557744B (zh) * 2014-12-23 2017-04-12 广东东阳光药业有限公司 一种三氮唑化合物的制备方法
WO2017088759A1 (en) 2015-11-23 2017-06-01 Sunshine Lake Pharma Co., Ltd. OCTAHYDROPYRROLO [3, 4-c] PYRROLE DERIVATIVES AND USES THEREOF
BR112018016446B1 (pt) 2016-02-12 2024-02-06 Eolas Therapeutics, Inc. Composto de piperidina halo-substituída, composição farmacêutica compreendendo dito composto e uso terapêutico dos mesmos
CA3059394C (en) 2017-05-03 2023-09-12 Idorsia Pharmaceuticals Ltd Preparation of 2-([1,2,3]triazol-2-yl)-benzoic acid derivatives
WO2020099511A1 (en) * 2018-11-14 2020-05-22 Idorsia Pharmaceuticals Ltd Benzimidazole-2-methyl-morpholine derivatives
GB201901142D0 (en) * 2019-01-28 2019-03-20 Heptares Therapeutics Ltd OX1 Antagonists
US20240116913A1 (en) 2021-02-02 2024-04-11 Idorsia Pharmaceuticals Ltd A crystalline form of (4-methyl-2-[1,2,3]triazol-2-yl-phenyl)-[(r)-3-(3-[1,2,3]triazol-2-yl-benzyl)-morpholin-4-yl]-methanone
TW202400149A (zh) * 2022-05-13 2024-01-01 瑞士商愛杜西亞製藥有限公司 經噻唑并芳基-甲基取代之環狀肼-n-甲醯胺衍生物
CN115947697A (zh) * 2022-12-28 2023-04-11 苏州汉德创宏生化科技有限公司 一种3-氧代吗啉-4-羧酸叔丁酯的合成方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5130432A (en) 1990-12-21 1992-07-14 Syntex (U.S.A.) Inc. Process for preparing cyclic amines and intermediate products thereof
PT100639A (pt) 1991-06-27 1993-09-30 Univ Virginia Commonwealth Metodo para o tratamento terapeutico com compostos que sao ligandos ao receptor sigma e compostos ai utilizados, nomeadamente derivados fenilalquil-amina, aminotetralina,piperazina e piperidina
JP2004534026A (ja) * 2001-05-05 2004-11-11 スミスクライン　ビーチャム　パブリック　リミテッド　カンパニー オレキシン受容体アンタゴニストとしてのｎ−アロイルサイクリックアミン誘導体
GB0115862D0 (en) 2001-06-28 2001-08-22 Smithkline Beecham Plc Compounds
BR0210609A (pt) * 2001-06-28 2004-07-20 Smithkline Beecham Plc Derivados de amina cìclica n-aroila como antagonistas do receptor da orexina
GB0124463D0 (en) * 2001-10-11 2001-12-05 Smithkline Beecham Plc Compounds
GB0130335D0 (en) 2001-12-19 2002-02-06 Smithkline Beecham Plc Compounds
WO2005118548A1 (en) 2004-03-01 2005-12-15 Actelion Pharmaceuticals Ltd Substituted 1,2,3,4-tetrahydroisoquinoline derivatives
JP4582722B2 (ja) 2006-03-15 2010-11-17 アクテリオン ファーマシューティカルズ リミテッド 記憶機能を向上させるテトラヒドロイソキノリン誘導体
CA2657623A1 (en) 2006-07-14 2008-01-17 Merck & Co., Inc. Bridged diazepan orexin receptor antagonists
GB0620818D0 (en) 2006-10-19 2006-11-29 Ucb Sa Therapeutic agents
PE20081229A1 (es) 2006-12-01 2008-08-28 Merck & Co Inc Antagonistas de receptor de orexina de diazepam sustituido
CN101874030B (zh) 2007-09-24 2012-11-14 埃科特莱茵药品有限公司 用作食欲素受体拮抗剂的吡咯烷和哌啶
PE20091010A1 (es) 2007-10-10 2009-08-08 Actelion Pharmaceuticals Ltd Derivados de tetrahidroquinolina
CA2739915A1 (en) * 2008-10-21 2010-04-29 Merck Sharp & Dohme Corp. 2,5-disubstituted piperidine orexin receptor antagonists
US8710076B2 (en) 2008-10-21 2014-04-29 Merck Sharp & Dohme Corp. 2,5-disubstituted piperidine orexin receptor antagonists
EP2349270B1 (en) 2008-10-21 2015-09-09 Merck Sharp & Dohme Corp. 2,5-disubstituted morpholine orexin receptor antagonists
BRPI0922353A2 (pt) 2008-12-02 2018-06-05 Glaxo Group Ltd Derivados de n-{[(1r,4s, 6r-3- (2-piridinilcarbonil) - 3azabiciclo [4.1.0] hept-4-il] metil}-2-heteroarilamina e usos dos mesmos
AU2009324239A1 (en) 2008-12-02 2010-06-10 Glaxo Group Limited N-{[(IR,4S,6R-3-(2-pyridinylcarbonyl)-3-azabicyclo [4.1.0]hept-4-yl] methyl}-2-heteroarylamine derivatives and uses thereof
EP2491034B1 (en) 2009-10-23 2013-12-18 Janssen Pharmaceutica, N.V. Fused heterocyclic compounds as orexin receptor modulators
KR20120105449A (ko) 2009-10-23 2012-09-25 얀센 파마슈티카 엔.브이. 오렉신 수용체 조절제로서의 이치환된 옥타하이드로피롤로［3,4-ｃ］피롤
WO2011050202A1 (en) 2009-10-23 2011-04-28 Janssen Pharmaceutica Nv Fused heterocyclic compounds as orexin receptor modulators

Also Published As

Publication number Publication date
CN103917538A (zh) 2014-07-09
HRP20160678T1 (hr) 2016-07-15
AU2012335194B2 (en) 2017-05-25
CN103917538B (zh) 2016-08-24
HK1199022A1 (zh) 2015-06-19
IL232462A (en) 2016-11-30
EP2776430A1 (en) 2014-09-17
BR112014010617A2 (pt) 2017-04-25
BR112014010617A8 (pt) 2017-12-26
EA201400553A1 (ru) 2014-10-30
HUE029239T2 (en) 2017-02-28
DK2776430T3 (en) 2016-05-09
CY1117638T1 (el) 2017-04-26
US9150566B2 (en) 2015-10-06
TWI555747B (zh) 2016-11-01
TWI565703B (zh) 2017-01-11
KR20140096338A (ko) 2014-08-05
BR112014010617B1 (pt) 2021-12-14
CA2846568A1 (en) 2013-05-16
MY167791A (en) 2018-09-26
SG11201401665WA (en) 2014-09-26
IN2014CN04127A (es) 2015-07-10
AU2012335194A1 (en) 2014-07-03
KR101676930B1 (ko) 2016-11-16
ZA201404189B (en) 2017-08-30
JP5718535B2 (ja) 2015-05-13
JP2014532753A (ja) 2014-12-08
EA024106B1 (ru) 2016-08-31
IL232462A0 (en) 2014-06-30
SI2776430T1 (sl) 2016-06-30
TW201323421A (zh) 2013-06-16
MX343837B (es) 2016-11-24
AR088692A1 (es) 2014-06-25
UA112317C2 (uk) 2016-08-25
ES2572703T3 (es) 2016-06-01
US20150158855A1 (en) 2015-06-11
NZ625896A (en) 2016-04-29
EP2776430B1 (en) 2016-03-16
WO2013068935A1 (en) 2013-05-16
CL2014000659A1 (es) 2014-08-18
TW201632517A (zh) 2016-09-16
PL2776430T3 (pl) 2016-09-30
CA2846568C (en) 2020-01-14

Similar Documents

Publication Publication Date Title
MX343837B (es) Derivados de 2 - (1,2,3 -triazol - 2 - il) benzamida y 3 - (1,2,3 - triazol - 2 - il) picolinamida.
MY169986A (en) Benzimidazole-proline derivatives
PH12015501339A1 (en) Indole carboxamide derivatives as p2x7 receptor antagonists
PH12014502363A1 (en) N-aryltriazole compounds as lpar antagonists
PH12014502789A1 (en) N-alkyltriazole compounds as lpar antagonists
PH12019500188A1 (en) Piperidine cxcr7 receptor modulators
PH12014501415A1 (en) Heterocyclic amide derivatives as p2x7 receptor antagonists
PH12014502364A1 (en) Substituted pyrazole compounds as lpar antagonists
PH12015502632A1 (en) Cxcr7 receptor modulators
MY176244A (en) Crystalline salt form of (s)-(2-(6-chloro-7-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonist
MX364610B (es) Derivados de 1- [m-carboxamido (hetero) aril-metil]-heterociclil-c arboxamida.
TN2016000061A1 (en) Amide derivatives as lysophosphatidic acid receptor antagonists
PH12016500134B1 (en) 1-(piperazin-1-yl) -2- ([1,2,4] triazol -1- yl) - ethanone derivatives
UA112586C2 (uk) Похідні бензімідазолпроліну
TH156808A (th) อนุพันธ์ 2-(1,2,3-ไทรอะซอล-2อิล)เบนซาไมด์ และ 3-(1,2,3-ไทรอะซอล-2-อิล)พิโคลินาไมด์

Legal Events

Date Code Title Description
FG Grant or registration